TY - JOUR
T1 - MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma
AU - Augello, Claudia
AU - Gianelli, Umberto
AU - Savi, Federica
AU - Moro, Alessia
AU - Bonoldi, Emanuela
AU - Gambacorta, Marcello
AU - Vaira, Valentina
AU - Baldini, Luca
AU - Bosari, Silvano
PY - 2014
Y1 - 2014
N2 - Aims: To identify molecular characteristics to hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) through a comprehensive miRNAs expression profiling. Methods: In this study, miRNA profiles were obtained from 37 patients with DLBCLs and 60 patients with reactive lymph nodes, equally distributed according to HCV presence. Germinal centres, from reactive lymph nodes were used as controls. Clinical features at presentation were available for all patients. Results: A set of 52 miRNAs define a signature for HCV-associated DLBCL. Importantly, decreased expression of miR-138-5p and increased expression of miR-147a, miR-147b and miR-511-5p in HCV DLBCL was found to be a poor prognostic factor for HCV-positive DLBCL patients. Conclusions: These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers.
AB - Aims: To identify molecular characteristics to hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) through a comprehensive miRNAs expression profiling. Methods: In this study, miRNA profiles were obtained from 37 patients with DLBCLs and 60 patients with reactive lymph nodes, equally distributed according to HCV presence. Germinal centres, from reactive lymph nodes were used as controls. Clinical features at presentation were available for all patients. Results: A set of 52 miRNAs define a signature for HCV-associated DLBCL. Importantly, decreased expression of miR-138-5p and increased expression of miR-147a, miR-147b and miR-511-5p in HCV DLBCL was found to be a poor prognostic factor for HCV-positive DLBCL patients. Conclusions: These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers.
UR - http://www.scopus.com/inward/record.url?scp=84905095831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905095831&partnerID=8YFLogxK
U2 - 10.1136/jclinpath-2014-202352
DO - 10.1136/jclinpath-2014-202352
M3 - Article
C2 - 24914240
AN - SCOPUS:84905095831
VL - 67
SP - 697
EP - 701
JO - Journal of Clinical Pathology - Clinical Molecular Pathology
JF - Journal of Clinical Pathology - Clinical Molecular Pathology
SN - 0021-9746
IS - 8
ER -